Date: 2014-01-15
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Astellas Pharma (Japan)
Product: ASP5878
Action
mechanism: FGFR inhibitor/tyrosine kinase inhibitor. ASP5878 is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR), with potential antineoplastic activity.
Disease: solid tumors
Therapeutic area: Cancer - Oncology
Country: Japan, USA
Trial
details: The objectives of this study are to determine the tolerability, safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of oral ASP5878 in patients with solid tumors. (NCT02038673)
Latest
news: * On January 15, 2014, a Phase I trial sponsored by Amgen was published on the NIH website ClinicalTrials.gov for ASP5878 and is currently recruiting participants.
